Disproportionate distal limb shortening is the hallmark of acromelic dysplasias. Among them, geleophysic dysplasia is a rare, frequently lethal condition characterized by severe short stature, musculoskeletal, cardiac, pulmonary, and skin anomalies. Geleophysic dysplasia results from dominant fibrillin-1 (FBN1) or recessive ADAMTSL2 mutations, suggesting a functional link between ADAMTSL2 and FBN1. Mice lacking ADAMTSL2 die at birth, precluding analysis of postnatal skeletal growth and mechanisms underlying the skeletal anomalies of geleophysic dysplasia. We show that Adamtsl2 is expressed in limb soft tissues, predominantly in tendon.
Introduction
structures in the ECM (21) . Microfibrils provide structural integrity to tissues and regulate members of the transforming growth factor (TGF)- superfamily by sequestering them directly (bone morphogenetic proteins) or via their binding to latent TGF binding proteins (22) (23) (24) . The genetics of human acromelic dysplasias suggests that ADAMTS proteins and FBN1 operate in the same pathway to regulate musculoskeletal development and growth, and that ADAMTSL2 could affect the structure and function of microfibrils. However, the specific roles and mechanisms of ADAMTSL2 at the tissue and molecular level during musculoskeletal development remain to be fully elucidated.
Adamtsl2 knockout mice die perinatally due to bronchial occlusion and a ventricular septal defect that precluded analysis of postnatal bone growth (25) . Notably, skeletal patterning and development were not impaired in the null embryos, suggesting the possibility of a defective longitudinal bone growth during the juvenile period. We previously showed that recombinant ADAMTSL2 bound not only to FBN1, but also to FBN2 (25) . FBN2, together with a third fibrillin isotype, FBN3 (present in humans but not in mice), is the embryonic fibrillin isotype, whereas FBN1 plays major roles in postnatal growth and tissue integrity (26) (27) (28) . On the basis of these findings, it was suggested that ADAMTSL2 may modulate the balance between embryonic and adult fibrillin isotypes in microfibrils (13) . Notably, In the Adamtsl2 knockout mice, fibrillin-2 (FBN2) microfibrils accumulated at the interface of bronchial smooth muscle cells and the bronchial epithelium (25) .
Here, we demonstrate that tissue-specific Adamtsl2 deletion, either in limb mesenchyme or tendons, recapitulates the skeletal phenotype of GD. These experiments, together with elucidation of additional in vitro mechanisms, provide new insights on mechanisms of geleophysic dysplasia with broad relevance to skeletal growth regulation and tendon development.
Results
Adamtsl2 mRNA is expressed in musculoskeletal soft tissues and presumptive articular cartilage, but not growth plate cartilage. The temporal and spatial pattern of Adamtsl2 mRNA expression during embryonic mouse musculoskeletal development and during postnatal growth was revealed by -galactosidase staining using an intragenic Adamtsl2-lacZ reporter transgene, which provided a surrogate for Adamtsl2 mRNA expression. At embryo age 14.5 (E14.5) and E17.5 whole limb staining showed that Adamtsl2 was most strongly expressed in developing tendons ( Figure 1A Figure 1L , arrows). In the vertebral column, we detected strong Adamtsl2 expression in the inner annulus fibrosus layer of the intervertebral disc, but not in the nucleus pulposus ( Figure 1N , Q).
Conditional Adamtsl2 deletion in limb-mesenchyme leads to acromelic dysplasia. To define the role of ADAMTSL2 in post-natal limb growth, we bypassed neonatal lethality of the Adamtsl2 null mice by using Prx1-Cre-mediated limb mesenchyme-specific inactivation of Adamtsl2 ( Figure 1P ) (25, 29) . PCR analysis of genomic DNA extracted from toes, but not from tail DNA indicated successful limb-specific excision of the floxed exon-5 of Adamtsl2 by Cre-recombinase (genotype referred to as Adamtsl2-Prx) ( Figure 1Q ). In addition, real-time quantitative PCR (RTqPCR) of Achilles tendon mRNA showed a significant reduction of Adamtsl2 mRNA in Adamtsl2-Prx mice compared to control tendons ( Figure 1R ). Adamtsl2-Prx mice were viable and without gross musculoskeletal anomalies.
Alizarin red-Alcian blue stained skeleton preparations from P16 to P20 demonstrated that Adamtsl2-Prx long bone diaphyses were less sculpted, i.e., they lacked a characteristic narrowing in the central diaphyseal regions and had a "stubby" appearance (2A, B, F-H, "D" indicates narrowest part of diaphyses). These changes were most visible in metacarpals and metatarsals ( Figure 2B , H). All forelimb bones were reduced in length in Adamtsl2-Prx mice ( Figure 2C, D) .
The distal bones were disproportionately shorter, indicating an acromelic limb phenotype. The diaphyseal and metaphyseal regions of Adamtsl2-Prx forelimb bones were significantly wider compared to controls ( Figure 2E ). Like the forelimbs, Adamtsl2-Prx hindlimb bones were also shorter and their diaphyseal and metaphyseal regions were significantly wider in Adamtsl2-Prx limbs ( Figure 2F -K). At birth (P0), metatarsals and radii of Adamtsl2-Prx mice were significantly shorter, but no significant differences were observed in the length of metacarpals and the ulna (Supplemental Figure 1A) . In Adamtsl2-Prx mice older than 9 months, significant bone shortening persisted in metatarsals and the tibia, but was not observed in the forelimb (metacarpals, humerus, radius, ulna) (Supplemental Figure 1B) . Neither histological abnormalities in the growth plate of Adamtsl2-Prx limbs nor differences in the height of the growth plate, or its proliferative, prehypertrophic and hypertrophic zones were detected (Supplemental Figure 2A, B) . In summary, limb-specific deletion of Adamtsl2 consistently resulted in distal bone shortening in the limbs and altered the shape of the diaphyseal and metaphyseal regions, i.e., recapitulating skeletal anomalies described in GD.
Abnormal Achilles tendon in Adamtsl2-Prx mice. In addition to the skeletal anomalies, Achilles tendons from Adamtsl2-Prx mice had altered dimensions and morphology ( Figure 3A, B) .
Specifically, their origins from the gastrocnemius were poorly defined, and they were significantly shorter and wider than controls ( Figure 3A, B) . During limb dissection, we also noticed that Adamtsl2-Prx Achilles tendons were tethered to surrounding tissue, reminiscent of severe peritendon fibrosis reported in Achilles tendon from dogs with Musladin-Lueke syndrome (10) . In contrast, the control Achilles tendons could be readily separated from the surrounding tissue.
Because tendons consist predominantly of collagen I fibrils and genetic loss of specific ECM components alters collagen fibril diameter (30) (31) (32) (33) , we analyzed the cross-sectional diameter of the collagen fibrils by transmission electron microcopy. The profiles of the collagen fibrils were regular and comparable in the two groups. Based on a two-sample Kolmogorov-Smirnov test, no significant difference in the distribution of the collagen fibril diameter was detected in Achilles tendon tissues from Adamtsl2-Prx limbs compared to control tendons ( Figure 3C, D) .
Given intense Adamtsl2 expression in tendons and pronounced morphological alterations in Adamtsl2-Prx Achilles tendons, we undertook tendon-specific Adamtsl2 deletion using Scx-Cre We showed previously that recombinant ADAMTSL2 directly bound to the N-and Cterminal halves of recombinant FBN1 and FBN2 (3, 25) . To discern whether ADAMTSL2 also bound to the corresponding supramolecular complexes, i.e., to fibrillin microfibrils, we added purified recombinant ADAMTSL2 to human dermal fibroblasts and asked whether it colocalized with endogenous fibrillin microfibrils. Recombinant ADAMTSL2 co-localized with both FBN1 and FBN2 microfibrils, but the colocalization with FBN2 was weaker because fewer FBN2-stained microfibrils were formed by these cells ( Figure 6A ). To capture early time points of microfibril formation and to analyze the potential co-localization of ADAMTSL2 with fibronectin fibrils, whose assembly precedes that of fibrillin microfibrils, we performed co-immunostaining experiments 24h after cell seeding and recombinant ADAMTSL2 supplementation ( Figure 6B ).
We found that ADAMTSL2 co-localized with nascent FBN1 microfibrils, but not with FBN2 at the 24h time point. ADAMTSL2 also co-localized to some, but not all, fibronectin-positive fibrils.
Given the previously published co-localization of FBN1 or FBN2 with fibronectin (34) and colocalization of FBN1 and FBN2 (35, 36) , our data suggest that ADAMTSL2 predominantly binds to FBN1 microfibrils in the ECM of human dermal fibroblasts. Taken together with increased FBN1 immunostaining in Adamtsl2-Prx tendons, the data suggest a specific regulatory role for ADAMTSL2 in limiting FBN1 levels in tendon microfibrils after birth.
Discussion
Here, we report generation and analysis of mouse models that recapitulate skeletal manifestations of human geleophysic dysplasia. Our studies identified an unexpected distribution of Adamtsl2 mRNA, showing its absence in cartilage growth plates, where skeletal growth occurs, but intense expression in tendons. Tendon-specific Adamtsl2 deletion suggested that ADAMTSL2 expressed by tendons and by implication, tendons themselves, non-autonomously regulate skeletal growth.
Intense Adamtsl2 expression in tendons, tenocyte disarray, ADAMTSL2 binding to fibrillin microfibrils and excess FBN1 microfibrils in tendons upon ADAMTSL2 deletion strongly suggests that ADAMTSL2 limits formation of fibrillin microfibrils in tendon pericellular matrix, and has a tissue-autonomous function in tendon.
Bone growth results from chondrocyte proliferation, hypertrophy and ECM synthesis at cartilage growth plates, located at the ends of long bones. The mediators of growth are well-characterized and include Indian hedgehog and parathyroid hormone-related protein acting locally in the growth plate, and endocrine factors such as growth hormone, and vitamin D (37) (38) (39) . Soft tissues have long been known to have a role in bone growth, surmised from limb shortening after soft tissue contractures, juvenile paralysis or experimental manipulation of soft tissues (40) (41) (42) .
The skeletal impact of soft tissue anomalies is thought to arise from mechanical constraints imposed by reduced soft tissue extensibility, consistent with retardation of growth plate activity by exogenous compressive force (43, 44) . Notably, all tendons cross at least one joint, allowing the muscle-tendon unit to exert compressive force on one or more growth plates. The lack of Adamtsl2 expression in growth plate cartilage suggests that a local, direct role on intrinsic cartilage growth control pathways is unlikely. In contrast, extremely strong Adamtsl2 expression in tendons, shortening of tendons observed after both Prx1-Cre and Scx-Cre-mediated conditional deletion, and clinically manifest peri-tendon fibrosis and contractures in patients with GD and dogs with Musladin-Lueke syndrome (9, 10, 45) support a specific role for ADAMTSL2 in tendon growth and a growth plate-extrinsic mechanism affecting long bone growth. Moreover, tendon-specific deletion with Scx-driven Cre, which, unlike Prx-Cre, spares recombination in cartilage, specifically led to bone shortening. The present studies have not formally excluded a potential biochemical regulatory pathway in which products released from tenocytes would act in an endocrine / paracrine fashion on the growth plate.
Previous work showed that linear tenocyte arrays in maturing tendons were specifically associated with fibrillin microfibrils, which were postulated to represent fiducial elements essential for tenogenesis (46) . Although our study showed that collagen fibrillogenesis was unimpaired, the findings suggest that accumulation of FBN1 in tendon microfibrils affects the overall growth and morphogenesis of the Achilles tendon, including the alignment and abundance of collagen fibers, which are higher-order collagen assemblies of fibrils. The observed minor differences in skeletal growth following Prx1-Cre and Scx-Cre mutagenesis may arise from different temporal and spatial deletion by these promoters. ADAMTSL2 deletion in muscle and skin by Prx1-Cre, where it was not deleted by Scx-Cre, may also contribute an additional impact on skeletal growth. Interestingly, Fbn1 deletion using Scx-Cre results in bone lengthening i.e., a mouse model for skeletal manifestations of Marfan syndrome (Dr. Francesco Ramirez, Icahn School of Medicine at Mount Sinai, personal communication). What is presently unclear is the genesis of the cortical diaphyseal and metaphyseal bone sculpting defect that was observed, since ADAMTSL2 is not expressed in bone of periosteum. We suggest that this could arise from the influence of contracted tendons and soft tissue in the juvenile period prior, since bone remodeling is sensitive to mechanical forces (47) .
At the molecular level, the prior demonstration that ADAMTSL2 binds to both FBN1 and FBN2, is extended here to demonstrate their binding to microfibrils which in addition to fibrillins, contain numerous other molecules (1, 25) . Previously, in embryos with global loss of ADAMTSL2, we identified an excess of FBN2 microfibrils in bronchial ECM associated with bronchial epithelial dysplasia and occlusion of bronchial lumena (25) . FBN2 is the major fibrillin expressed during embryogenesis, with FBN1 expressed at relatively low levels until the end of gestation (26, 27) . At birth, which represents a watershed in fibrillin gene expression, FBN2 expression wanes and FBN1 becomes the dominant fibrillin isotype in mice. Thus, in addition to FBN2 accumulation in embryonic Adamtsl2-/-bronchi, intense FBN1 staining was seen in postnatal Adamtsl2-deficient Achilles tendon. These findings, taken together with the observation that ADAMTSL2 has at least two binding sites on both fibrillin isotypes (1, 48) , suggest a general function for ADAMTSL2 in limiting microfibril assembly, i.e., ADAMTSL2 may suppress microfibril formation independent of fibrillin isotype (3, 25) . However, when recombinant ADAMTSL2 was added to human dermal fibroblasts, no consistent change in the amount of fibrillin microfibril staining was observed. One possibility is that dermal fibroblasts do not recapitulate the precise expression of microfibril proteins and ADAMTS proteins as tenocytes.
Alternatively, ADAMTSL2 may modulate protease activity in the ECM, interfering with microfibril turnover in tissues. Since FBN2 and FBN1 microfibrils accumulated in the absence of ADAMTSL2 in vivo, ADAMTSL2 may act as a positive regulator of protease activity against microfibrils in vivo. In this regard, mutation of two ADAMTS proteases, ADAMTS10 and ADAMTS17 results in acromelic dysplasias, and ADAMTS10 has limited proteolytic activity against fibrillin-1 (49). These mechanisms have not been tested in cultured tenocytes, which do not retain the specific tenocyte phenotype in culture.
The enduring paradox of FBN1 mutations is that the majority cause MFS, but a subset of mutations, located in the fifth transforming growth factor-like / 8-cysteine domain of FBN1 (exons 41 and 42), lead to acromelic dysplasias, whose manifestations are the opposite of MFS.
Jensen et al demonstrated that MFS-causing FBN1 mutations affected molecular secretion, and could thus have a haploinsufficiency effect, whereas FBN1 mutants causing GD, which affect a specific domain, TB5, were secreted and assembled into microfibrils (50) . TB5 mutants leading to GD block the binding of this domain to heparan-sulfate, which regulates microfibril assembly (51).
Our findings regarding ADAMTSL2-fibrillin microfibril interactions on the one hand, and the effect of TB5 of mutations on the other, would support a role for a specific interaction between ADAMTSL2 and TB5 that inhibits microfibril assembly.
In summary, we present a novel mouse model for acromelic dysplasia recapitulating skeletal anomalies of GD. We discovered that shortening of the Achilles tendon in the absence of ADAMTSL2 influences bone growth, presumably by creating a biomechanical restraint on bone growth. An important direction for future investigation is how ADAMTSL2 regulates tenocyte alignment and influences tendon growth and collagen assembly.
Methods
All reagents were purchased from Sigma-Aldrich or ThermoFisher Scientific unless specified.
Mouse strains. Adamtsl2-Prx mice were generated by deleting the Frt-site-flanked lacZ-neo cassette from Adamtsl2 +/-mice (KOMP allele: Adamtsl2 tm1a(KOMP)Wtsi , NIH, Bethesda, MD, USA) using B6.Cg-Tg(ACTB-FLPe)9205Dym/J (Jackson Laboratory, Bar Harbor, ME USA) (25) . FLPe (FLP recombinase)-mediated deletion generated the Adamtsl2 fl allele, where exon 5 is flanked by loxP sites and is amenable to Cre-mediated excision ( Figure 1D) . A B6.Cg-Tg(Prrx1-cre)1Cjt/J (Prx1-Cre) male mouse was obtained from Jackson Laboratory and the Scx-Cre strain was previously described (52) .
Genotyping. Genomic DNA from toe and tail tissue was isolated using DirectPCR (Viagen, Los Angeles, CA, USA). PCR products were amplified using Taq polymerase (New England BioLabs Inc., Ipswich, MA, USA) and a forward primer located in exon 4 (Adamtsl2 wild-type allele, P1:
5´-gtaccagctctgcagagtgc-3´) in combination with reverse primers located in the En2-splice acceptor site in the lacZ-neo (Adamtsl2 knock-out allele, P2: 5´-cactgagtctctggcatctc-3´) or in exon 6 (Adamtsl2 wild-type or conditional allele, respectively, P3: 5´-ctctcaggtcggtgagcttg-3´).
PCR products were separated by agarose gel electrophoresis and visualized with ethidium bromide.
-Galactosidase (-gal) staining. Tissue was fixed in 4% paraformaldehyde (Electron Microscopy
Sciences, Hatfield, PA, USA) overnight and stained with potassium ferrocyanide/potassium ferricyanide/5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) (Denville Scientific Inc., Holliston, MA, USA) as described previously (53) .
Bone and tendon morphometry. Limbs were dissected, and the Achilles tendon exposed and photographed in situ. The soft tissue was removed, and bones were fixed in 80% ethanol and dehydrated in 96% ethanol and acetone over several days for Alizarin red / Alcian blue staining.
Staining was performed with a solution of 30 mg Alcian blue and 5 mg Alizarin red in 20 ml acetic acid / 80 ml 95% ethanol for several days at room temperature. Tissues were rinsed with 95%
ethanol and cleared with 1% aqueous potassium hydroxide followed by serial transfer in 20%, 50% and 80% glycerin prepared in 1% aqueous potassium hydroxide. Cleared and stained bones were photographed, and bone length was measured using Image J (NIH, Bethesda, MD and antigen retrieval was performed with citrate-EDTA for 4 x 1.5 min in a microwave oven.
Sections were cooled in antigen-retrieval buffer rinsed with water and 2 x PBS and blocked for 1h
in 5% normal goat serum in PBS. Sections were incubated with FBN1 antibody (54) diluted in blocking buffer overnight at 4 °C, rinsed 3 X 10 min in PBS, and incubated with secondary antibody (goat anti-rabbit-Alexa-564) (Jackson ImmunoResearch, West Grove, PA, USA) diluted in blocking buffer for 1h at RT. Sections were rinsed 3 X 10 min in PBS and mounted using
VectaShield Gold with DAPI. Sections were photographed on an Olympus BX51 upright microscope (Olympus, Center Valley, PA, USA) using a Leica DFC7000T camera and Leica Application Suite v4.6 imaging software (Leica Microsystems, Wetzlar, Germany).
Second-harmonic generation / Two-photon imaging
Paraformaldehyde-fixed, paraffin-embedded tendon sections were rehydrated and coverslipped in 50% glycerol in PBS. Images were acquired using a Leica TCS SP5 II Confocal/Multi-Photon high-speed upright microscope with a 25X water immersion lens in forward scattering mode (Leica Microsystems). The excitation wavelength was set to 880 nm and the non-descanned detector 
